FindMyRecallSubscribe
Class II: temporary or reversible health riskOngoing

Teva Pharmaceuticals Isotretinoin Capsules Recall

Isotretinoin Capsules, USP 40mg, 30-count 3x10 blister packs per carton, Rx Only, Manu…

Teva Pharmaceuticals USA, Inc · Parsippany, NJ

Risk level
Class II
Reported by FDA
Apr 17, 2024
Recall ID
D-0439-2024
Check your lot numberHow we source this data

Summary

Teva Pharmaceuticals recalled Isotretinoin Capsules starting Mar 28, 2024. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0439-2024 on Apr 17, 2024. Reason: Superpotent Drug: The 3-month stability result for assay was found to be above specification limit. Status: Ongoing.

Why it was recalled

Superpotent Drug: The 3-month stability result for assay was found to be above specification limit

Product description

Isotretinoin Capsules, USP 40mg, 30-count 3x10 blister packs per carton, Rx Only, Manufactured For: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054. Blister Pack NDC 0591-2436-45, Carton NDC 0591-2436-15

Lot numbers, UPCs & expiration codes

Lot #: 100044259, Exp 06/30/2025.

Where it was sold

Nationwide in the USA

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0439-2024
Classification
Class II
Status
Ongoing
Recall initiated
Mar 28, 2024
FDA report date
Apr 17, 2024
Quantity
5,304 3x10-cartons
Recall type
Voluntary: Firm initiated
Recalling firm
Teva Pharmaceuticals USA, Inc

Original FDA data

Every field from FDA enforcement report D-0439-2024, exactly as published.

Show all FDA fields
City
Parsippany
State
NJ
Status
Ongoing
Country
United States
Event ID
94294
Address
400 Interpace Pkwy Bldg A
Code information
Lot #: 100044259, Exp 06/30/2025.
Postal code
07054-1120
Report date
Apr 17, 2024
Product type
Drugs
Recall number
D-0439-2024
Classification
Class II
Recalling firm
Teva Pharmaceuticals USA, Inc
Product quantity
5,304 3x10-cartons
Reason for recall
Superpotent Drug: The 3-month stability result for assay was found to be above specification limit
Voluntary / mandated
Voluntary: Firm initiated
Product description
Isotretinoin Capsules, USP 40mg, 30-count 3x10 blister packs per carton, Rx Only, Manufactured For: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054. Blister Pack NDC 0591-2436-45, Carton NDC 0591-2436-15
Distribution pattern
Nationwide in the USA
Recall initiation date
Mar 28, 2024
Initial firm notification
Letter
Center classification date
Apr 8, 2024

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0439-2024, published Apr 17, 2024. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls